United States Cardiovascular Drugs Market Key Players, Industry Overview, Supply and Consumption Demand Analysis to 2025
26th September 2018 - The United
States Cardiovascular Drug Market displayed robust growth in
assessment years. Cardiovascular disease is a fatal disease striking heart and
related blood vessel disorders. They take on names as ischemic heart disease,
dyslipedimia, stroke, thrombosis, atheroscelorosis, coronary artery diseases
and likes. Cardiovascular diseases are diseases that strike the heart and block
blood vessels. The various drugs available for treating cardiovascular diseases
belong to a special class of medicines that target arrhythmia, myocardial
infection and atherosclerosis. Anti-hypertensive drugs segment will hold
dominant share of cardiovascular drugs market while anti-hyperlipidemcis
segment slid up to top position to rake in market contribution in forecast
period.
An
enhanced population base that attracts high hospital visits on account of
cardiovascular disease will demonstrate growth in hospital pharmacies segment.
These disorders are linked to obesity, high cholesterol, smoking, excess
alcohol and poor lifestyle. CVD is a major mortality source across the globe
and more so with adults.
View Full Report
with TOC @ https://www.millioninsights.com/industry-reports/united-states-cardiovascular-drug-market
Cardiovascular
diseases can be prevented with systematic and timely medication. The drugs
ingested either enhance systolic rate of heart or act in enhancing supply of
oxygen-rich blood to heart. Significant drugs prescribed for treatment
cardiovascular diseases includes heparin, Coumadin, warfarin, sectral
(acebutolol), Zebeta (bisoprolol), Lopressor, Toprol XL (metoprolol), Norvasc,
Amlodipine, vascor and sular (nisoldipine).
Antihypersensitive
drugs hold dominance amongst CVD market share in terms of growth revenue and
this stage of growth is primarily attributed by presence of multibillion dollar
drugs such as Diovan and Benicar. Thrombolytic brands hold smaller fraction of
total share as compared to antihypersensitive drugs but are projected to be
fast movers forcing pace of growth of cardiovascular drugs market by revenue
growth. North America accounts for largest share of market because of
significant awareness of heart diseases and furthermore heart diseases striking
people in America. Segmentation of United States Cardiovascular Drug Market by
drug class includes antihyperlipidemics, antihypertensive, anti-coagulants,
antifibrinolytic, antiarryhtmic.
Segmentation
of United States Cardiovascular Drug Market by distribution channel includes
retail pharmacies, hospital pharmacies and online pharmacies. The key players
in United States Cardiovascular Drug Market include Astra Zeneca, plc., Pfizer,
Inc., Sanofi and Johnson and Johnson.
Market Segment:
Geographically, this report splits the
United States market into seven regions:
•
The West
•
Southwest
•
The Middle Atlantic
•
New England
•
The South
•
The Midwest
with
sales (volume), revenue (value), market share and growth rate of Cardiovascular
Drugs in these regions, from 2013 to 2025 (forecast).
United States Cardiovascular Drugs
market competition by top manufacturers/players, with Cardiovascular Drugs
sales volume, price, revenue (Million USD) and market share for each
manufacturer/player; the top players including
•
AstraZeneca
•
Pfizer Inc
•
Novartis AG
•
Merck
•
Bristol-Myers Squibb
•
Bayer AG
•
Sanofi
•
Boehringer Ingelheim GmbH
•
F. Hoffmann-La Roche
Request Sample
Copy of This Report @ https://www.millioninsights.com/industry-reports/united-states-cardiovascular-drug-market/request-sample
Comments
Post a Comment